Previous close | 155.50 |
Open | 155.50 |
Bid | 155.60 |
Ask | 161.75 |
Strike | 860.00 |
Expiry date | 2025-12-19 |
Day's range | 155.50 - 155.50 |
Contract range | N/A |
Volume | |
Open interest | 196 |
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand. What does that mean for the marketplace?
Eli Lilly's (LLY) GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports more on the story and what it means for competitors, like Novo Nordisk (NVO). For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Melanie Riehl
Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.